Denali Therapeutics Inc.

Based in South San Francisco, Denali Therapeutics is a biopharmaceutical company focused on discovering and developing therapeutics for neurodegenerative diseases and lysosomal storage disorders. The company's pipeline spans multiple modalities and targets, including small molecule inhibitors, enzyme replacement therapies, and antibody-based programs. Key programs include Eclitasertib for peripheral inflammatory diseases, DNL343 for amyotrophic lateral sclerosis, BIIB122 for Parkinson's disease, and DNL310 for Hunter Syndrome. The company has also established a proprietary Enzyme TransportVehicle platform designed to deliver therapies across the blood-brain barrier, with programs addressing Pompe disease, Parkinson's disease, Gaucher disease, and Hurler syndrome.

The company's clinical and preclinical portfolio targets rare genetic disorders and common neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, and frontotemporal dementia. Denali operates through partnerships and collaborations, including programs developed with Biogen and Takeda Pharmaceutical. Founded in 2013 as SPR Pharma and rebranded as Denali Therapeutics in 2015, the company has built a research and development organization centered on enzyme replacement and neurological therapeutics.